MELLODDY: Cross-pharma Federated Learning at Unprecedented Scale Unlocks Benefits in QSAR without Compromising Proprietary Information.

Federated multipartner machine learning has been touted as an appealing and efficient method to increase the effective training data volume and thereby the predictivity of models, particularly when the generation of training data is resource-intensive. In the landmark MELLODDY project, indeed, each of ten pharmaceutical companies realized aggregated improvements on its own classification or regression models through federated learning. To this end, they leveraged a novel implementation extending multitask learning across partners, on a platform audited for privacy and security. The experiments involved an unprecedented cross-pharma data set of 2.6+ billion confidential experimental activity data points, documenting 21+ million physical small molecules and 40+ thousand assays in on-target and secondary pharmacodynamics and pharmacokinetics. Appropriate complementary metrics were developed to evaluate the predictive performance in the federated setting. In addition to predictive performance increases in labeled space, the results point toward an extended applicability domain in federated learning. Increases in collective training data volume, including by means of auxiliary data resulting from single concentration high-throughput and imaging assays, continued to boost predictive performance, albeit with a saturating return. Markedly higher improvements were observed for the pharmacokinetics and safety panel assay-based task subsets.

ChemGrapher: Optical Graph Recognition of Chemical Compounds by Deep Learning.

In drug discovery, knowledge of the graph structure of chemical compounds is essential. Many thousands of scientific articles and patents in chemistry and pharmaceutical sciences have investigated chemical compounds, but in many cases, the details of the structure of these chemical compounds are published only as an image. A tool to analyze these images automatically and convert them into a chemical graph structure would be useful for many applications, such as drug discovery. A few such tools are available and they are mostly derived from optical character recognition. However, our evaluation of the performance of these tools reveals that they often make mistakes in recognizing the correct bond multiplicity and stereochemical information. In addition, errors sometimes even lead to missing atoms in the resulting graph. In our work, we address these issues by developing a compound recognition method based on machine learning. More specifically, we develop a deep neural network model for optical compound recognition. The deep learning solution presented here consists of a segmentation model, followed by three classification models that predict atom locations, bonds, and charges. Furthermore, this model not only predicts the graph structure of the molecule but also provides all information necessary to relate each component of the resulting graph to the source image. This solution is scalable and can rapidly process thousands of images. Finally, we empirically compare the proposed method with the well-established tool OSRA1 and observe significant error reduction.